ARQT: Arcutis Biotherapeutics Inc

ARQT News

• Zacks 14:00 Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
• Benzinga 12:34 This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Applied Optoelectronics (NASDAQ:AAOI), Arcutis Biotherapeutics (NASDAQ:ARQT)
• Investing 11:56 Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth
• Investor's Business Daily 22:55 Netflix Among 9 Stocks Elevated To IBD Best Growth Stock Lists: Who's On The IBD 50, Other Premium Lists?
• Investor's Business Daily 16:25 Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196%
• Investing 20:04 Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise
• Investor's Business Daily 23:02 Western Digital In 9-Week Win Streak, On 2 Top Stock Watchlists: Check Out IBD 50, Stock Spotlight, Others
• Investor's Business Daily 07:00 Arcutis Biotherapeutics Stock Scores RS Rating Upgrade
• Investing 14:17 Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating
• Seeking Alpha 03:25 Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction (NASDAQ:ARQT)
• Investing 12:59 Arcutis’ ZORYVE ® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
• Seeking Alpha 02:40 AMG GW&K Small Cap Core Fund Q1 2025 Commentary
• Seeking Alpha 08:43 Arcutis Biotherapeutics Stock: Another Approval Under Their Belt (NASDAQ:ARQT)
• Seeking Alpha 03:57 Arcutis Stock: Out Of The Woods, Ready For Commercialization. (NASDAQ:ARQT)
• Seeking Alpha 14:10 PGIM Jennison Health Sciences Fund Q1 2025 Commentary (PHLAX)
• Investing 14:00 Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE ® (roflumilast)  Cream 0.05% in Infants with Atopic Dermatitis
• Investing 11:27 H.C. Wainwright maintains $19 target on Arcutis stock
• Investing 20:20 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Benzinga 15:11 Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Arcutis Biotherapeutics (NASDAQ:ARQT)
• Investing 12:12 Arcutis to Present New Long-Term Results of ZORYVE ® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
• Seeking Alpha 05:07 Arcutis Stock: Navigating Commercialization With Promising Upside (NASDAQ:ARQT)
• Investing 11:46 H.C. Wainwright reiterates buy rating and $19 target on Arcutis stock
• Investing 00:31 Arcutis Biotherapeutics SVP sells $24,806 in stock
• Investing 21:08 Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference